Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124
Tweet Send to a Friend
Mizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
